MA44637A1 - Composes hétérocycliques et leurs utilisations - Google Patents

Composes hétérocycliques et leurs utilisations

Info

Publication number
MA44637A1
MA44637A1 MA44637A MA44637A MA44637A1 MA 44637 A1 MA44637 A1 MA 44637A1 MA 44637 A MA44637 A MA 44637A MA 44637 A MA44637 A MA 44637A MA 44637 A1 MA44637 A1 MA 44637A1
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
preparation
methods
relates
present
Prior art date
Application number
MA44637A
Other languages
English (en)
Other versions
MA44637B1 (fr
Inventor
Mingda Bi
Robert Kuehl
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of MA44637A1 publication Critical patent/MA44637A1/fr
Publication of MA44637B1 publication Critical patent/MA44637B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne certaines formulations pharmaceutiques d'omécamtiv mécarbil et leurs procédés de préparation et d'utilisation.
MA44637A 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations MA44637B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (fr) 2013-03-14 2014-03-14 Composés hétérocycliques et leurs utilisations

Publications (2)

Publication Number Publication Date
MA44637A1 true MA44637A1 (fr) 2019-08-30
MA44637B1 MA44637B1 (fr) 2021-04-30

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38399A MA38399B2 (fr) 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MA44637A MA44637B1 (fr) 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38399A MA38399B2 (fr) 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique

Country Status (43)

Country Link
US (16) US9951015B2 (fr)
EP (3) EP2968173B1 (fr)
JP (5) JP6498658B2 (fr)
KR (2) KR102374159B1 (fr)
CN (3) CN108785265B (fr)
AP (1) AP2015008789A0 (fr)
AR (2) AR095542A1 (fr)
AU (2) AU2014240049C1 (fr)
BR (2) BR112015022857B1 (fr)
CA (2) CA3147180C (fr)
CL (1) CL2015002708A1 (fr)
CR (1) CR20150549A (fr)
CY (2) CY1122695T1 (fr)
DK (2) DK2970123T4 (fr)
EA (1) EA031185B1 (fr)
ES (2) ES2837038T3 (fr)
FI (1) FI2970123T4 (fr)
HK (1) HK1218080A1 (fr)
HR (2) HRP20201967T1 (fr)
HU (2) HUE046285T2 (fr)
IL (2) IL240788B (fr)
JO (1) JOP20140114B1 (fr)
LT (2) LT2970123T (fr)
MA (2) MA38399B2 (fr)
ME (1) ME03566B (fr)
MX (3) MX2015012429A (fr)
MY (2) MY204971A (fr)
NZ (1) NZ711225A (fr)
PE (1) PE20151786A1 (fr)
PH (2) PH12019500176B1 (fr)
PL (2) PL2968173T3 (fr)
PT (2) PT2968173T (fr)
RS (2) RS59536B1 (fr)
RU (1) RU2663663C2 (fr)
SA (1) SA515361088B1 (fr)
SG (2) SG11201507258PA (fr)
SI (2) SI2970123T2 (fr)
SM (2) SMT201900563T1 (fr)
TN (1) TN2015000380A1 (fr)
TW (1) TWI667026B (fr)
UA (1) UA117011C2 (fr)
UY (1) UY35449A (fr)
WO (2) WO2014152270A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
US11608318B2 (en) * 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (fr) 2018-12-18 2020-06-25 Amgen Inc. Procédé de réduction de composés nitro aromatiques
JP2022524609A (ja) 2019-03-12 2022-05-09 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形及び共結晶
EP3938042A1 (fr) * 2019-03-12 2022-01-19 Amgen Inc. Polymorphes d'un activateur de troponine cardiaque
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
WO2021053189A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220402874A1 (en) * 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CA3168513A1 (fr) * 2020-02-10 2021-08-19 Amgen Inc. Comprime d'omecamtiv mecarbil
JP7825954B2 (ja) * 2020-08-26 2026-03-09 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2024081611A1 (fr) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (fr) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil destiné à être utilisé dans le traitement de l'insuffisance cardiaque par activation d'un sarcomere cardiaque

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
AU783685B2 (en) 1999-12-23 2005-11-24 Pfizer Products Inc. Hydrogel-driven drug dosage form
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
CA2463682A1 (fr) 2001-10-17 2003-04-24 Aventis Pharma Deutschland Gmbh Methode de reduction du diabete type 2 chez des patients a risque eleve
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
WO2007054975A1 (fr) 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes
PE20070823A1 (es) 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1962852B1 (fr) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Composes, compositions et methodes
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
WO2010040110A1 (fr) 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Procédés et compositions pour le traitement de l’insuffisance cardiaque aiguë
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
AU2014240104B2 (en) * 2013-03-14 2018-11-08 Amgen Inc. Heterocyclic compounds and their uses
CA2975260C (fr) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (fr) 2018-12-18 2020-06-25 Amgen Inc. Procédé de réduction de composés nitro aromatiques
WO2021053189A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4041710A1 (fr) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Nouveaux procédés destinés à la préparation de l'omécamtiv mécarbil
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CA3168513A1 (fr) 2020-02-10 2021-08-19 Amgen Inc. Comprime d'omecamtiv mecarbil
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
TW201524507A (zh) 2015-07-01
CN108785265A (zh) 2018-11-13
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
AP2015008789A0 (en) 2015-10-31
CN105209437B (zh) 2018-09-18
CR20150549A (es) 2016-01-04
RS61215B1 (sr) 2021-01-29
IL241089B (en) 2019-10-31
US10421726B2 (en) 2019-09-24
AR095542A1 (es) 2015-10-21
MX2015012429A (es) 2016-04-07
IL240788B (en) 2020-09-30
CA2902646C (fr) 2022-08-16
US12583821B2 (en) 2026-03-24
FI2970123T4 (fi) 2026-03-20
EP2970123B2 (fr) 2025-12-10
HK1218080A1 (zh) 2017-02-03
TWI667026B (zh) 2019-08-01
SG10201706656RA (en) 2017-09-28
PH12015501998A1 (en) 2016-01-11
RS59536B1 (sr) 2019-12-31
KR20150136063A (ko) 2015-12-04
LT2970123T (lt) 2019-11-11
AR129504A2 (es) 2024-09-04
UY35449A (es) 2014-09-30
JP2016513683A (ja) 2016-05-16
HK1218544A1 (en) 2017-02-24
PH12015501998B1 (en) 2016-01-11
CN105120844A (zh) 2015-12-02
MA38399A1 (fr) 2017-01-31
AU2014239995B2 (en) 2018-07-26
HRP20201967T1 (hr) 2021-03-05
LT2968173T (lt) 2021-03-25
JP2022023891A (ja) 2022-02-08
ES2837038T3 (es) 2021-06-29
WO2014152236A1 (fr) 2014-09-25
US12275704B2 (en) 2025-04-15
JP2016519071A (ja) 2016-06-30
MX2021001231A (es) 2021-04-12
US12221417B2 (en) 2025-02-11
US20160016906A1 (en) 2016-01-21
SMT202000685T1 (it) 2021-01-05
EP2968173A1 (fr) 2016-01-20
US9988354B2 (en) 2018-06-05
US20200079736A1 (en) 2020-03-12
CY1122695T1 (el) 2021-03-12
SI2970123T2 (sl) 2026-04-30
MX2015012414A (es) 2016-04-25
KR102474467B1 (ko) 2022-12-05
HUE052355T2 (hu) 2021-04-28
UA117011C2 (uk) 2018-06-11
BR112015022857B1 (pt) 2022-10-25
JOP20140114B1 (ar) 2021-08-17
NZ750950A (en) 2020-09-25
SMT201900563T1 (it) 2019-11-13
US20140309235A1 (en) 2014-10-16
BR112015023417A2 (pt) 2017-07-18
US20200331859A1 (en) 2020-10-22
AU2014239995A1 (en) 2015-09-10
US11384053B2 (en) 2022-07-12
KR102374159B1 (ko) 2022-03-15
SI2968173T1 (sl) 2021-04-30
NZ711225A (en) 2020-06-26
MA38399B2 (fr) 2020-12-31
SI2970123T1 (sl) 2019-12-31
US20240317687A1 (en) 2024-09-26
HRP20191728T1 (hr) 2019-12-13
PH12019500176B1 (en) 2023-08-11
SG11201507258PA (en) 2015-10-29
CA3147180A1 (fr) 2014-09-25
IL241089A0 (en) 2015-11-30
AU2014240049C1 (en) 2019-03-07
TN2015000380A1 (en) 2017-01-03
CY1123633T1 (el) 2022-03-24
KR20220045014A (ko) 2022-04-12
BR112015022857A2 (pt) 2017-07-18
EP3821882A1 (fr) 2021-05-19
MY204971A (en) 2024-09-25
SA515361088B1 (ar) 2018-07-22
CA2902436A1 (fr) 2014-09-25
EP2970123A1 (fr) 2016-01-20
JP2019059746A (ja) 2019-04-18
PT2968173T (pt) 2020-12-18
EP2970123B1 (fr) 2019-08-14
EA201591728A1 (ru) 2016-01-29
EA031185B1 (ru) 2018-11-30
AU2014240049A1 (en) 2015-09-10
HK1218512A1 (zh) 2017-02-24
US20180273479A1 (en) 2018-09-27
US20250376444A1 (en) 2025-12-11
US20200399221A1 (en) 2020-12-24
RU2663663C2 (ru) 2018-08-08
ME03566B (fr) 2020-07-20
JP6498658B2 (ja) 2019-04-10
CA3147180C (fr) 2024-04-23
US11472773B2 (en) 2022-10-18
ES2750676T3 (es) 2020-03-26
ES2750676T5 (en) 2026-03-12
US11884630B2 (en) 2024-01-30
JP2020125307A (ja) 2020-08-20
IL240788A0 (en) 2015-10-29
PH12019500176A1 (en) 2020-11-04
JP6966590B2 (ja) 2021-11-17
US20220153700A1 (en) 2022-05-19
MY186048A (en) 2021-06-17
DK2968173T3 (da) 2020-12-21
RU2015143643A (ru) 2017-04-18
US20230044617A1 (en) 2023-02-09
CN108785265B (zh) 2024-10-08
WO2014152270A1 (fr) 2014-09-25
EP2968173B1 (fr) 2020-10-14
JP6689942B2 (ja) 2020-04-28
US20240101517A1 (en) 2024-03-28
HUE046285T2 (hu) 2020-02-28
PL2970123T3 (pl) 2020-03-31
US20200277261A1 (en) 2020-09-03
PL2968173T3 (pl) 2021-03-08
DK2970123T3 (da) 2019-10-21
HK1219484A1 (zh) 2017-04-07
PE20151786A1 (es) 2015-12-11
US20250243163A1 (en) 2025-07-31
PT2970123T (pt) 2019-10-28
JP7174132B2 (ja) 2022-11-17
CL2015002708A1 (es) 2016-03-11
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
DK2970123T4 (da) 2026-01-26
BR112015023417B1 (pt) 2023-10-17
US20220298114A1 (en) 2022-09-22
CA2902646A1 (fr) 2014-09-25
AU2014240049B2 (en) 2018-07-19
JP6783138B2 (ja) 2020-11-11
CN105209437A (zh) 2015-12-30

Similar Documents

Publication Publication Date Title
MA44637B1 (fr) Composes hétérocycliques et leurs utilisations
MA53356A (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
EP2866791A4 (fr) Nouvelles compositions et utilisations d'agents antihypertenseurs pour thérapie anticancéreuse
EP2892559A4 (fr) Formulations d'anticorps et leurs utilisations
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
MX2015012416A (es) Compuestos heterociclicos y sus usos.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation
EP2958573A4 (fr) Formulations pharmaceutiques de nitrite et leurs utilisations
FR3010999B1 (fr) Glycoclusters et leurs utilisations pharmaceutiques en tant qu'antibacteriens
TR201010859A2 (tr) Sefdinir içeren tablet formları.
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
MA35947B1 (fr) Anticorps et immunoconjugués anti-lgr5